|
BE787901A
(fr)
|
1971-09-11 |
1972-12-18 |
Freistaat Bayern Represente Pa |
Vaccin antivariolique
|
|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
DK0538496T3
(da)
|
1991-08-26 |
2004-02-23 |
Baxter Healthcare Sa |
Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
|
|
WO1994012617A1
(en)
|
1992-11-25 |
1994-06-09 |
International Biotechnology Laboratories, Inc. |
Hepatitis b virus vaccines
|
|
AU4088697A
(en)
|
1996-08-26 |
1998-03-19 |
Chiron Corporation |
Postinfection human immunodeficiency virus (hiv) vaccination therapy
|
|
AUPP380598A0
(en)
|
1998-05-29 |
1998-06-25 |
Commonwealth Scientific And Industrial Research Organisation |
Genetically manipulated entomopoxvirus
|
|
US6294176B1
(en)
|
1998-07-10 |
2001-09-25 |
Schering-Plough Veterinary Corp. |
Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
|
|
JP4554887B2
(ja)
|
2001-03-08 |
2010-09-29 |
アメリカ合衆国 |
改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
|
|
WO2003078640A2
(en)
|
2002-03-15 |
2003-09-25 |
Baxter International Inc. |
Recombinant drug-sensitive vaccinia virus as smallpox vaccine
|
|
ATE315660T1
(de)
|
2002-05-16 |
2006-02-15 |
Bavarian Nordic As |
Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
|
|
US9045727B2
(en)
*
|
2002-05-17 |
2015-06-02 |
Emory University |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
CA2501168A1
(en)
|
2002-11-25 |
2004-06-10 |
Bavarian Nordic A/S |
Recombinant poxvirus comprising at least two cowpox ati promoters
|
|
EP2363493B1
(en)
|
2003-02-20 |
2012-11-14 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Novel insertion sites in pox vectors
|
|
US20070092936A1
(en)
|
2003-05-08 |
2007-04-26 |
Haynes Barton F |
Severe acute respiratory syndrome
|
|
US8080642B2
(en)
*
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
|
US8541003B2
(en)
|
2003-06-20 |
2013-09-24 |
Protein Sciences Corporation |
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
|
|
CN1918288A
(zh)
*
|
2003-06-20 |
2007-02-21 |
蛋白质科学公司 |
表达sars免疫原的载体、含所述载体或其表达产物的组合物、制备和使用方法和实验
|
|
WO2005047459A2
(en)
*
|
2003-08-04 |
2005-05-26 |
University Of Massachusetts |
Sars nucleic acids, proteins, antibodies, and uses thereof
|
|
WO2006071250A2
(en)
|
2004-04-05 |
2006-07-06 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Soluble fragments of the sars-cov spike glycoprotein
|
|
CA2569142A1
(en)
*
|
2004-06-02 |
2005-12-22 |
New York Blood Center |
Sars vaccines and methods to produce highly potent antibodies
|
|
JPWO2006022215A1
(ja)
*
|
2004-08-23 |
2008-05-08 |
財団法人ヒューマンサイエンス振興財団 |
ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
|
|
US9453239B2
(en)
|
2004-08-27 |
2016-09-27 |
Emory University |
Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
|
|
CA2587084C
(en)
*
|
2004-10-08 |
2019-07-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by using less frequently used synonym ous codons
|
|
CN100479858C
(zh)
*
|
2005-01-27 |
2009-04-22 |
中国医学科学院实验动物研究所 |
一种重组痘苗-sars疫苗及其制备方法
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
DK2062023T4
(en)
|
2006-08-25 |
2017-02-20 |
The Government Of The Us Secretary Dept Of Health And Human Services |
INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
|
|
JP5683476B2
(ja)
|
2008-11-03 |
2015-03-11 |
タケダ ヴァクシーンズ， インコーポレイテッド |
感染因子を含まないエンベロープウイルスベースｖｌｐを単離するための改良法
|
|
AP2012006258A0
(en)
|
2009-10-13 |
2012-06-30 |
Geovax Inc |
Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
|
|
DK2488649T3
(da)
|
2009-10-16 |
2019-06-17 |
Us Health |
Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
|
|
WO2011103417A2
(en)
|
2010-02-18 |
2011-08-25 |
Emory University Of Technology Transfer |
Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
|
|
TWI526539B
(zh)
*
|
2010-12-22 |
2016-03-21 |
苜蓿股份有限公司 |
植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
|
|
WO2013059498A1
(en)
|
2011-10-18 |
2013-04-25 |
Geovax, Inc. |
Mva vectors expressing polypeptides and having high level production in certain cell lines
|
|
US20150140068A1
(en)
|
2012-07-06 |
2015-05-21 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
WO2015009946A1
(en)
|
2013-07-17 |
2015-01-22 |
Emory University |
Method of increasing immune response to hiv antigens
|
|
WO2015066715A1
(en)
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
ES2851451T3
(es)
|
2014-05-13 |
2021-09-07 |
Bavarian Nordic As |
Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
|
|
EP3188752A2
(en)
|
2014-09-03 |
2017-07-12 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
WO2016068919A1
(en)
|
2014-10-29 |
2016-05-06 |
Geovax, Inc. |
Combination therapy for treating viral reservoirs
|
|
US11701418B2
(en)
|
2015-01-12 |
2023-07-18 |
Geovax, Inc. |
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
|
|
EP3045181B1
(en)
|
2015-01-19 |
2018-11-14 |
Ludwig-Maximilians-Universität München |
A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
|
|
WO2017120577A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Geovax Inc. |
Compositions and methods for generating an immune response to a tumor associated antigen
|
|
RS61118B1
(sr)
*
|
2016-01-12 |
2020-12-31 |
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh |
Sredstva i postupci za lečenje hbv
|
|
WO2017136419A1
(en)
|
2016-02-03 |
2017-08-10 |
Geovax Inc. |
Compositions and methods for generating an immune response to a flavivirus
|
|
EP3416978A4
(en)
|
2016-02-16 |
2019-11-06 |
Geovax, Inc. |
MULTIVALENT HIV VACCINE BOOST COMPOSITION AND METHOD OF USE
|
|
WO2017210181A1
(en)
|
2016-05-30 |
2017-12-07 |
Geovax Inc. |
Compositions and methods for generating an immune response to hepatitis b virus
|
|
US10960070B2
(en)
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
IL288737B
(en)
|
2017-02-01 |
2022-09-01 |
Atea Pharmaceuticals Inc |
Hemisulfate nucleotide salt for treatment of hepatitis c virus
|
|
EP3595676A4
(en)
*
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
WO2018195447A1
(en)
|
2017-04-20 |
2018-10-25 |
Geovax Labs, Inc. |
Recombinant mva-based hiv immunogens and uses thereof
|
|
WO2019018501A1
(en)
|
2017-07-18 |
2019-01-24 |
Geovax Inc. |
COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE
|
|
WO2019040846A1
(en)
|
2017-08-25 |
2019-02-28 |
Geovax Inc. |
IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|
|
JP2023512519A
(ja)
|
2020-01-31 |
2023-03-27 |
ベス イスラエル ディーコネス メディカル センター インコーポレイテッド |
コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
|
|
CA3168836A1
(en)
|
2020-02-03 |
2021-08-12 |
City Of Hope |
Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
|
|
WO2021163365A1
(en)
|
2020-02-11 |
2021-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 vaccine
|
|
GB2594683A
(en)
|
2020-02-17 |
2021-11-10 |
Vaxbio Ltd |
Vaccine
|
|
KR20220165731A
(ko)
*
|
2020-02-26 |
2022-12-15 |
토닉스 파마 리미티드 |
Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신
|
|
JP2023517286A
(ja)
|
2020-03-13 |
2023-04-25 |
オックスフォード ユニヴァーシティ イノヴェーション リミテッド |
免疫応答を誘導するための組成物及び方法
|
|
TW202200199A
(zh)
|
2020-03-20 |
2022-01-01 |
美商百歐恩泰美國公司 |
冠狀病毒疫苗及使用方法
|
|
WO2021194826A2
(en)
|
2020-03-24 |
2021-09-30 |
Icahn School Of Medicine At Mount Sinai |
Recombinant sars-cov-2 spike protein and uses thereof
|
|
US20210299245A1
(en)
|
2020-03-31 |
2021-09-30 |
Sementis Limited |
Attenuated poxvirus vector based vaccine for protection against covid-19
|
|
US20240285751A1
(en)
|
2020-04-01 |
2024-08-29 |
Diosynvax Ltd |
Coronavirus vaccines
|
|
US20230143228A1
(en)
|
2020-04-21 |
2023-05-11 |
Emory University |
Coronavirus vaccines, compositions, and methods related thereto
|
|
EP4153228A4
(en)
|
2020-05-17 |
2024-07-10 |
City of Hope |
CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
|
|
US11130787B2
(en)
*
|
2020-06-11 |
2021-09-28 |
MBF Therapeutics, Inc. |
Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
|
|
EP3928789A1
(en)
*
|
2020-06-24 |
2021-12-29 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
JP2024505274A
(ja)
|
2021-02-02 |
2024-02-05 |
ゲオバックス インコーポレイテッド |
ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
|